The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

What separates KL-50 from other chemotherapy drugs is its remarkable selectivity ... it was fundraising,” Lin told the News.

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

Merck, known as MSD outside the United ... HIV and their communities for the collaboration that made today’s approval possible.” Both drugs, administered orally once daily, are indicated ...

That made it the largest contributor to Merck's total quarterly sales of $16.1 billion. Ongoing clinical trials and further ...

Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...

Merck, a leading science and technology company, today announced a € 70 million expansion of its ADC manufacturing ...

but lacks a ready-made Keytruda replacement. Investors should monitor R&D updates closely, as Merck's future hinges on new drug developments amid looming patent expirations. Keytruda is now under ...

The drug has played an instrumental role in driving ... for treating adjuvant melanoma and non-small cell lung cancer. Merck made meaningful regulatory and clinical progress this year across ...

He made the remarks as the company participated ... in China with breakthrough technologies in areas like mRNA, antibody-drug ...